Patents Examined by Sudhakar Katakam
  • Patent number: 10472320
    Abstract: The present invention relates to a process to prepare N,N?-di(2-hydroxybenzyl) ethylenediamine-N,N?-diacetic acid and salts thereof (HBED) comprising a reaction between formaldehyde, ethylenediamine diacetic acid or a salt thereof (EDDA) and phenol, wherein the reaction mixture contains 0.2 to 1.1 molar equivalents of alkali metal ions on the basis of the molar amount of EDDA and the reaction mixture is processed by a step in which at least part of the organic compounds other than the formed HBED are removed from the reaction mixture, and optionally recycled, during which step at least 50% and up to and including 100% of the alkali metal ions in the reaction mixture are potassium ions, to products obtainable by such process and their use.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: November 12, 2019
    Assignee: NOURYON CHEMICALS INTERNATIONAL B.V.
    Inventors: Adrianus Maria Reichwein, Hubertus Johannes Jongen, Marjolein Groote
  • Patent number: 10464880
    Abstract: The present invention relates to a method for the purification of cadaverine from an aqueous cadaverine salt composition comprising one or more involatile impurities, the method comprising: (1) mixing the aqueous cadaverine salt composition with one or more bases to provide an aqueous cadaverine composition having a pH of at least about 12; (2) distilling or evaporating the aqueous cadaverine composition to produce an aqueous cadaverine solution, wherein one or more solvents are added to the evaporation/distillation system before the evaporation/distillation stops, and the one or more solvents comprise at least one or more high boiling point (HBP) solvents having a boiling point of at least 185° C. (1 atm); and (3) subjecting the aqueous cadaverine solution to one or more rectification steps to provide a cadaverine product.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: November 5, 2019
    Assignees: CATHAY BIOTECH INC., CIBT AMERICA INC.
    Inventors: Xiucai Liu, Charlie Liu, Bingbing Qin, Naiqiang Li, Yang Chen
  • Patent number: 10468722
    Abstract: Processes and reaction mixtures including non-aqueous solvent mixtures are presented. Non-aqueous solvent mixtures including fluoride salt and non-aqueous solvent combinations are provided that possess high fluoride ion concentrations useful for a range of applications, including organic synthesis. Further non-aqueous solvent mixtures are provided including a salt possessing a non-fluoride anion and a non-aqueous solvent that, when contacted with aqueous fluoride-containing reagents, extract fluoride ions to form non-aqueous fluoride-ion solutions possessing high fluoride-ion concentrations. The salts include an organic cation that does not possess a carbon in the ?-position or does not possess a carbon in the ?-position having a bound hydrogen. This salt structure facilitates its ability to be made anhydrous without decomposition. Example anhydrous fluoride salts include (2,2-dimethylpropyl)trimethylammonium fluoride and bis(2,2-dimethylpropyl)dimethylammonium fluoride.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: November 5, 2019
    Assignees: California Institute of Technology, The Regents of the University of California
    Inventors: Simon C. Jones, Victoria K. Davis, Christopher M. Bates, Nebojsa Momcilovic, Brett M. Savoie, Michael A. Webb, Thomas F. Miller, III, Robert H. Grubbs, Jennifer M. Murphy
  • Patent number: 10463670
    Abstract: Use of the non-peptide NK1 receptor antagonist, preferably Aprepitant, for the treatment of cancer in predetermined doses. The present invention also describes pharmaceutical compositions comprising said agents, alone or in combination with at least one other active principle, for the treatment of cancer.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: November 5, 2019
    Assignee: SERVICIO ANDALUZ DE SALUD
    Inventor: Manuel Vicente Salinas Martín
  • Patent number: 10463717
    Abstract: The invention relates to a composition in the form of an injectable aqueous solution, of which the pH is from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic radicals Hy having the following formula I: *GpRrGpAaGpC)p ??I characterized in that the composition does not comprise a basal insulin of which the isoelectric point pI is from 5.8 to 8.5. It also relates to a composition characterized in that it moreover comprises a prandial insulin.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: November 5, 2019
    Assignee: ADOCIA
    Inventors: David Duracher, Gregory Meiffren, Remi Soula
  • Patent number: 10457706
    Abstract: Water dispersible, multivalent ligand-lipid constructs that spontaneously and stably incorporate into membranes are disclosed.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 29, 2019
    Inventors: Stephen Micheal Henry, Elena Korchagina, Igor Leonidovich Rodionov, Alexander Borisovich Tuzikov
  • Patent number: 10449256
    Abstract: The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 6.6 and 7.8, including at least: a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and b) a hydrophobized anionic polymer. In one embodiment, the compositions according to the invention also include a prandial insulin.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: October 22, 2019
    Assignee: ADOCIA
    Inventors: Olivier Soula, Richard Charvet
  • Patent number: 10450262
    Abstract: A method for purifying 1,4-diaminobutane comprising the steps of: separating a second composition including carbonate salt of 1,4-diaminobutane from a first composition including carbonate salt of 1,4-diaminobutane by distillation; and removing carbonate from carbonate salt of 1,4-diaminobutane included in the second composition to recover 1,4-diaminobutane.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: October 22, 2019
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Won Sik Gwak, Hong Xian Li, Hyun Ju Won, Hyo Hyoung Lee, Kyung Su Na, Su Jin Park, Young Lyeol Yang, Hye Won Um, Chang Yub Oh, Kyoung Min Lee
  • Patent number: 10449165
    Abstract: Described herein are methods, compositions, systems, and kits that effectively deliver a laxative to a patient along with effective electrolyte replenishment by delivering both a laxative and electrolytes via a food item. The food item is prepared by either combining, mixing, or integrating the ingredients that form the food item together with one of or both of a laxative and electrolytes so that the ingredients in the food item either eliminate or significantly reduce the poor taste associated with either the electrolytes or the laxative. Eliminating or reducing the poor taste associated with either electrolytes or laxative, greatly improves patient satisfaction and compliance with ingesting these substances in order to, for example, prepare the GI tract of the patient for a medical or surgical procedure.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: October 22, 2019
    Assignee: COLONARYCONCEPTS LLC
    Inventors: Michael Allio, Jonathan Gordon
  • Patent number: 10434181
    Abstract: The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: October 8, 2019
    Assignee: Nektar Therapeutics
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier, Neel K. Anand
  • Patent number: 10426162
    Abstract: The invention provides activated or inactivated compositions combining quaternary ammonium compounds and anionic surfactants or acids. The invention further provides activated or inactivated compositions combining quaternary ammonium compounds and anionic chelants or polymers. Activated antimicrobial compositions comprised of a quaternary ammonium compound having less than a C20 chain length, and an anionic carboxylate surfactant having C6-C10 chain length are disclosed. Activated compositions of the invention have a pH of between about 1 and 7 and are substantially free of silanes, sulfates and oxidants. Inactivated antimicrobial compositions comprised of a quaternary ammonium compound having less than a C-20 chain length, and an anionic sulfate or sulfonate surfactant are disclosed. Compositions of the invention have a 10 mole to 1 moles ratio of quaternary ammonium compound to anionic surfactant or about 1 mole to 10 moles ratio. Methods of making and employing the compositions are disclosed.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 1, 2019
    Assignee: Ecolab USA Inc.
    Inventors: Victor Fuk-Pong Man, Derrick Richard Anderson
  • Patent number: 10428080
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: October 1, 2019
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Srinivasa Karra, Yufang Xiao
  • Patent number: 10426783
    Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 1, 2019
    Assignees: KYUSHU UNIVERSITY, NAT'L UNIVERSITY CORPORATION, KOWA COMPANY, LTD.
    Inventors: Tatsuro Ishibashi, Shintaro Nakao, Ryoichi Arita, Ken Mizuno, Akifumi Tsuchiura
  • Patent number: 10420736
    Abstract: The present invention addresses the problem of providing an intraocular irrigating solution that allows the intraocular tissue to be sufficiently protected during ophthalmic surgery and further has high safety. The problem is solved by an intraocular irrigating solution containing at least one of active sulfur molecules of which examples include cysteine persulfide and glutathione persulfide.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 24, 2019
    Assignee: TOHOKU UNIVERSITY
    Inventors: Toru Nakazawa, Takaaki Akaike, Hiroshi Kunikata
  • Patent number: 10413610
    Abstract: The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: September 17, 2019
    Assignee: LUODA PHARMA LIMITED
    Inventors: Nicholas Bova, Stephen Page, Giuseppe Pippia
  • Patent number: 10413585
    Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: September 17, 2019
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Volker Cleeves, Stephan Urban, Ralf Kubitz
  • Patent number: 10407386
    Abstract: This invention relates to a method of preparing D-arginine, and more particularly to a method of preparing D-arginine by optically resolving DL-arginine using D-3-bromocamphor-8-sulfonic acid or a salt thereof as an optical resolving agent.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: September 10, 2019
    Assignee: AMINOLOGICS CO., LTD.
    Inventors: Il-Suk Byun, Jung-Ho Lee, Hye-Lim Ga, Won-Sup Kim
  • Patent number: 10391101
    Abstract: This present disclosure generally relates to medicine, and in particular to pharmacology and psychiatry, and discloses active agents and related methods of treatment which can be used for the treatment of treatment-resistant forms of schizophrenia. In some exemplary aspects, such treatments allow for eliminating both the positive and negative symptoms of schizophrenia, and cognitive disorders, without causing severe side effects that limit their use, such as sedation, tachycardia, orthostatism, agranulocytosis and sialorrhea.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: August 27, 2019
    Assignee: VALENTEK LLC
    Inventors: Maksim E. Zapolski, Margarita A. Morozova, Allan G. Beniashvili
  • Patent number: 10385099
    Abstract: Macrocyclization of amino acids or linear peptides upon reaction with amphoteric amino aldehydes and isocyanides is provided.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: August 20, 2019
    Assignee: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Andrei Yudin, Ryan Hili
  • Patent number: 10383918
    Abstract: Physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, includes at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In an embodiment, the compositions include, in addition, a gastrointestinal hormone.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: August 20, 2019
    Assignee: ADOCIA
    Inventors: Alexandre Geissler, Ségolène Laage, Olivier Soula, David Duracher, Grégory Meiffren